Elke K Friedman

Learn More
PURPOSE Sorafenib, an oral multikinase inhibitor, has shown preliminary activity in non-small-cell lung cancer (NSCLC). Patients with advanced NSCLC were treated with erlotinib with or without(More)
4659 Background: Pazopanib, a multi-targeted inhibitor of VEGFR, PDGFR, and c-KIT, is an active first-line agent in the treatment of advanced renal cell carcinoma (RCC). The efficacy of pazopanib in(More)
  • 1